Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.

  • Paul G Richardson, Jacob Laubach, +9 authors Kenneth Anderson
  • Published 2010 in Oncology
Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high beta2-microglobulin, and… (More)